[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,036,211
  • Shares Outstanding, K 64,708
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -130,150 K
  • EBIT $ 58 M
  • EBITDA $ 54 M
  • 60-Month Beta 1.78
  • Price/Sales 212.93
  • Price/Cash Flow N/A
  • Price/Book 11.57

Options Overview Details

View History
  • Implied Volatility 43.50% (-0.51%)
  • Historical Volatility 47.44%
  • IV Percentile 20%
  • IV Rank 23.57%
  • IV High 69.06% on 07/13/26
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 4) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 46
  • Volume Avg (30-Day) 182
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 7,811
  • Open Int (30-Day) 7,494
  • Expected Range 157.16 to 157.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.19
  • Number of Estimates 4
  • High Estimate $3.27
  • Low Estimate $0.65
  • Prior Year $-0.62
  • Growth Rate Est. (year over year) +453.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.63 +20.23%
on 07/30/26
157.60 -0.34%
on 08/17/26
+16.15 (+11.46%)
since 07/17/26
3-Month
92.75 +69.34%
on 06/02/26
157.60 -0.34%
on 08/17/26
+54.88 (+53.71%)
since 05/15/26
52-Week
54.50 +188.18%
on 09/09/25
157.60 -0.34%
on 08/17/26
+100.99 (+180.11%)
since 08/15/25

Most Recent Stories

More News
Protagonist Therapeutics: Q2 Earnings Snapshot

Protagonist Therapeutics: Q2 Earnings Snapshot

PTGX : 157.03 (+1.24%)
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption

PTGX : 157.03 (+1.24%)
Protagonist Therapeutics: When Pipeline Promise Meets Revenue Reality Check

Barchart Research What to Expect from PTGX Earnings PTGX Generated August 4, 2026 Current Price $135.81 EPS Estimate $$2.11 Consensus Rating Strong Buy Average Move 3.21% Protagonist Therapeutics: When...

PTGX : 157.03 (+1.24%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance...

PTGX : 157.03 (+1.24%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 157.03 (+1.24%)
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks. PTGX holds a 100% “Buy” technical opinion from Barchart. Despite bullish analyst sentiment...

PTGX : 157.03 (+1.24%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 157.03 (+1.24%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 157.03 (+1.24%)
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will...

PTGX : 157.03 (+1.24%)
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer,...

PTGX : 157.03 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 163.72
2nd Resistance Point 159.63
1st Resistance Point 157.36
Last Price 157.03
1st Support Level 151.00
2nd Support Level 146.91
3rd Support Level 144.64

See More

52-Week High 157.60
Last Price 157.03
Fibonacci 61.8% 118.22
Fibonacci 50% 106.05
Fibonacci 38.2% 93.88
52-Week Low 54.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.